News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Actavis Chairman Offers $4.5 Billion for Drug Company
May 11, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
STOCKHOLM/LONDON, May 10 (Reuters) - Iceland's Actavis (ACT.IC: Quote, Profile , Research) said an investment firm led by its own chairman planned to make a $4.5 billion bid for the generic drugmaker, sending its shares sharply higher on Thursday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
IPO
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
July 21, 2026
·
3 min read
·
Gabrielle Masson
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
July 20, 2026
·
3 min read
·
Heather McKenzie
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 17, 2026
·
1 min read
·
Gabrielle Masson
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac